LAURA EICKELMANN: Open Payments
NPI 1821405028 · RENTON, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$430 in 12 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $140 · 2025 $430
Food & beverage: $430
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 1 | $150 |
| Lilly USA, LLC | 3 | $69 |
| ABBVIE INC. | 2 | $49 |
| UCB, Inc. | 1 | $46 |
| Teva Pharmaceuticals USA, Inc. | 1 | $35 |
| Neurelis, Inc. | 2 | $34 |
| Eisai Inc. | 1 | $29 |
| Integra LifeSciences Corporation | 1 | $17 |
Products named: AMVUTTRA, KISUNLA, Rystiggo, AUSTEDO XR, VALTOCO, QULIPTA, Leqembi, UBRELVY.
Industry payments across WA — which companies pay providers there.
